Skip to main content

Drug Interactions between deuruxolitinib and Luvox CR

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

fluvoxaMINE deuruxolitinib

Applies to: Luvox CR (fluvoxamine) and deuruxolitinib

CONTRAINDICATED: Concomitant administration with moderate or potent inhibitors of CYP450 2C9 may increase the plasma concentrations of deuruxolitinib, which is primarily metabolized via this isoenzyme. A model-informed approach predicted that coadministration with multiple doses of a potent CYP450 2C9 inhibitor with a single 12 mg dose of deuruxolitinib (1.5 times the approved 8 mg dose) would increase deuruxolitinib systemic exposure (AUC) by 200% and peak plasma concentration (Cmax) by 25%. Similarly, coadministration of deuruxolitinib (12 mg) with multiple doses of fluconazole 200 mg, a dual moderate CYP450 3A4 and CYP450 2C9 inhibitor, increased deuruxolitinib's AUC and Cmax by 140% and 21%, respectively. Additionally, individuals who are poor metabolizers of CYP450 2C9 are expected to have higher exposure of deuruxolitinib, which may increase the risk serious adverse reactions such as thrombosis. Based on drug-drug interaction modeling data, CYP450 2C9 poor metabolizers may have up to 2-fold higher concentration of deuruxolitinib, when compared to normal metabolizers. Pharmacokinetic data of deuruxolitinib for individuals who are intermediate metabolizers have not been evaluated.

MANAGEMENT: Concomitant use of deuruxolitinib with moderate or potent inhibitors of CYP450 2C9 is considered contraindicated.

References (1)
  1. (2024) "Product Information. Leqselvi (deuruxolitinib)." Sun Pharmaceutical Industries

Drug and food/lifestyle interactions

Moderate

fluvoxaMINE food/lifestyle

Applies to: Luvox CR (fluvoxamine)

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References (4)
  1. Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
  2. Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
  3. (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
  4. (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc
Moderate

deuruxolitinib food/lifestyle

Applies to: deuruxolitinib

MONITOR: Smoking during treatment with deuruxolitinib may increase the risk of major adverse cardiovascular events (MACE) and the risk of developing malignancies. In clinical studies of deuruxolitinib, individuals who were current or former smokers had an additional increased risk of overall malignancies. Also, deuruxolitinib may increase patients' risk of MACE, including myocardial infarction, stroke, and cardiovascular death.

MANAGEMENT: Caution is advised if deuruxolitinib is prescribed to current or past smokers. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur. The manufacturer recommends discontinuing deuruxolitinib in patients that have experienced a myocardial infarction or stroke. Deuruxolitinib may be taken with or without food.

References (1)
  1. (2024) "Product Information. Leqselvi (deuruxolitinib)." Sun Pharmaceutical Industries

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer